###begin article-title 0
Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 381 386 <span type="species:ncbi:9606">women</span>
The estrogen receptor alpha (ESR1) is a mediator of estrogen response in the breast. The most studied variants in this gene are the PvuII and XbaI polymorphisms, which have been associated to lower sensitivity to estrogen. We evaluated whether these polymorphisms were associated with breast cancer risk by means of an association study in a population of Caucasian postmenopausal women from the Rotterdam study and a meta-analysis of published data.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 57 62 <span type="species:ncbi:9606">women</span>
###xml 63 75 <span type="species:ncbi:9606">participants</span>
The PvuII and XbaI polymorphisms were genotyped in 3,893 women participants of the Rotterdam Study. Baseline information was obtained through a questionnaire. We conducted logistic regression analyses to assess the risk of breast cancer by each of the ESR1 genotypes. Meta-analyses of all publications on these relations were done by retrieving literature from Pubmed and by further checking the reference lists of the articles obtained.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 14 19 <span type="species:ncbi:9606">women</span>
There were 38 women with previously diagnosed breast cancer. During follow-up, 152 were additionally diagnosed. The logistic regression analyses showed no difference in risk for postmenopausal breast cancer in carriers of the PvuII or XbaI genotypes neither in overall, incident or prevalent cases. No further evidence of a role of these variants was found in the meta-analysis.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 117 122 <span type="species:ncbi:9606">women</span>
Our results suggest that the ESR1 polymorphisms do not play a role in breast cancer risk in Caucasian postmenopausal women.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 152 153 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 286 287 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
Family history is one of the strongest risk factors for breast cancer [1]. It has been shown that the heritability of this disease is approximately30% [2]. The most important determinants of risk for breast cancer are related to endogenous hormone levels and major reproductive events [3], thus, suggesting that genes in the estrogen pathway may influence breast cancer risk.
###end p 11
###begin p 12
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 437 441 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 523 524 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 526 527 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 729 730 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 732 733 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 805 809 805 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 905 906 905 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 259 264 <span type="species:ncbi:9606">human</span>
The estrogen receptor alpha (ESR1) is one of the most important mediators of hormonal response in estrogen-sensitive tissues such as the breast [4] and plays a crucial role in breast growth and differentiation as well as in the development of cancer [5]. The human ESR1 gene is localized on chromosome 6q24-q27 [6], it extends more than 140 kb and includes eight exons [7]. The most studied variants in this gene are the PvuII (C/T) and XbaI (G/A) polymorphisms in intron 1, 397 and 351 bp upstream of exon 2 respectively [8, 9]. These variants have been implicated in gene expression by influencing transcription [10]. While some studies have found an increased risk for the A and T alleles of the XbaI and PvuII polymorphisms [4, 9, 10], others have found an increased risk only for the X (G) allele of XbaI [11, 12]. In addition, other studies found no effect at all for either of these polymorphisms [4, 13]. These alleles were correlated with high bone mineral density and height in other studies, including one performed in our study population, [14, 15], suggesting a stronger estrogenic effect in P(C) and X(G) allele carriers [14].
###end p 12
###begin p 13
###xml 187 192 <span type="species:ncbi:9606">women</span>
The aim of our study was to evaluate the effect of these polymorphisms on breast cancer risk by performing an association analysis in a population based study of Caucasian postmenopausal women. Further, we performed meta-analyses of all available published data on these polymorphisms and the risk of breast cancer.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
Study population and measurements
###end title 15
###begin p 16
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 194 206 <span type="species:ncbi:9606">participants</span>
###xml 370 375 <span type="species:ncbi:9606">women</span>
Our study population is part of the Rotterdam study [16]. Inhabitants of the suburb of Ommoord aged 55 or older were invited to participate and 7983 agreed to do so (response rate 78.1%). Study participants signed an informed consent and the Medical Ethics Committee of the Erasmus Medical Center approved the study. Our study group was composed of 4,878 postmenopausal women. Information on risk factors such as age at entry, age at menarche, age at menopause, parity, body mass index (BMI), waist hip ratio (WHR) and hormone replacement therapy use (HRT) was retrieved at baseline through a questionnaire. BMI was calculated by dividing the weight in kilograms by the height (in meters) squared [17].
###end p 16
###begin title 17
Case identification and validation
###end title 17
###begin p 18
###xml 40 47 <span type="species:ncbi:9606">patient</span>
###xml 363 375 <span type="species:ncbi:9606">participants</span>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
Three different databases were used for patient identification. First, cases diagnosed by general practitioners in the research area (Ommoord) were collected (International Classification of Primary Care (code X76)). Second, the Dutch National Registry of all hospital admissions (LMR) was consulted to detect all malignancy related hospital admissions for study participants. Finally, regional pathology databases were linked to the Rotterdam Study to identify patients. Subsequently, breast cancer cases were validated by a physician on the basis of medical records of the general practitioner, discharge letters and pathology reports. Only pathologically confirmed cases were considered in the analysis. The index date was defined as the earliest date found in the pathology report.
###end p 18
###begin title 19
Genotyping & data analysis
###end title 19
###begin p 20
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 714 719 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 729 733 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1135 1137 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 17 22 <span type="species:ncbi:9606">women</span>
Out of the 4,878 women participating in our study, 3,893 (80 %) were successfully genotyped for the PvuII and XbaI polymorphisms. The genotyping procedures have been described previously [14]. Loss to follow up was assessed to verify it was independent of genotype. Categorical variables, such as parity and HRT, were compared between genotype groups using the chi-squared test. Continuous variables, (age at entry, age at menopause, BMI and WHR) were compared using the independent sample Mann-Whitney test. We used logistic regression to study the risk of breast cancer by ESR1 genotype. This analysis was performed using SPSS version 11, since there is no clear risk allele from the literature, we took the TT (PvuII) and AA (XbaI) genotypes as reference because they have been associated to lower sensitivity to estrogen in our population [14]. We also performed a trend test to evaluate if the number of risk alleles carried had an effect on disease risk. Hardy-Weinberg equilibrium (HWE) was assessed for both polymorphisms using Markov-Chain Monte-Carlo approximation of the exact test implemented in the GENEPOP package V 3.3 [18].
###end p 20
###begin title 21
Meta-analysis
###end title 21
###begin p 22
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">.</italic>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 859 860 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 860 861 860 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
We searched PubMed until October 2006 for all case-control studies on the association of the PvuII and XbaI polymorphisms in the ESR1 gene and breast cancer. Our search strategy was based on the keyword "breast cancer" combined with "estrogen receptor" and "polymorphism". To verify that all studies were retrieved, the reference lists of all publications were searched for additional studies. We excluded studies from our analyses if the genotype frequencies in the control population were out of Hardy-Weinberg or if their data had been previously used in another study. To quantify the strength of association, pooled odds ratios (ORs) and 95% confidence intervals (CI) were calculated using the random-effects model of the DerSimonian and Laird method [19]. The degree of heterogeneity between the study results was tested by the inconsistency statistic (I2). Funnel plots were used to evaluate publication bias [20]. Data were analysed using Review Manager, version 4.2 (Cochrane Collaboration, Oxford, UK).
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 195 197 195 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 552 553 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 580 581 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 682 683 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 813 820 813 820 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 820 867 820 867 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25">General characteristics of the study population</p>
###xml 820 867 820 867 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25">General characteristics of the study population</p></caption>
###xml 867 867 867 867 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 867 872 867 872 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cases</th>
###xml 872 880 872 880 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Controls</th>
###xml 880 885 880 885 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Total</th>
###xml 867 885 867 885 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Cases</th><th align="left">Controls</th><th align="left">Total</th></tr>
###xml 867 885 867 885 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Cases</th><th align="left">Controls</th><th align="left">Total</th></tr></thead>
###xml 885 902 885 902 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Total studied (%)</td>
###xml 902 912 902 912 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">190 (4.7%)</td>
###xml 912 923 912 923 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3513 (95.3)</td>
###xml 923 927 923 927 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3703</td>
###xml 885 927 885 927 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Total studied (%)</td><td align="left">190 (4.7%)</td><td align="left">3513 (95.3)</td><td align="left">3703</td></tr>
###xml 927 950 927 950 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean age of entry (SD)*</td>
###xml 950 961 950 961 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">67.80 (7.7)</td>
###xml 961 972 961 972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">70.36 (9.6)</td>
###xml 972 983 972 983 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">70.24 (9.6)</td>
###xml 927 983 927 983 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean age of entry (SD)*</td><td align="left">67.80 (7.7)</td><td align="left">70.36 (9.6)</td><td align="left">70.24 (9.6)</td></tr>
###xml 983 1006 983 1006 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean age at death (SD)*</td>
###xml 1006 1017 1006 1017 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">77.30 (8.6)</td>
###xml 1017 1028 1017 1028 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">84.46 (8.7)</td>
###xml 1028 1039 1028 1039 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">84.12 (8.8)</td>
###xml 983 1039 983 1039 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean age at death (SD)*</td><td align="left">77.30 (8.6)</td><td align="left">84.46 (8.7)</td><td align="left">84.12 (8.8)</td></tr>
###xml 1039 1064 1039 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean age at menarche (SD)</td>
###xml 1064 1075 1064 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13.57 (1.7)</td>
###xml 1075 1086 1075 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13.68 (1.8)</td>
###xml 1086 1097 1086 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13.67 (1.8)</td>
###xml 1039 1097 1039 1097 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean age at menarche (SD)</td><td align="left">13.57 (1.7)</td><td align="left">13.68 (1.8)</td><td align="left">13.67 (1.8)</td></tr>
###xml 1097 1124 1097 1124 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean age at menopause (SD)*</td>
###xml 1124 1135 1124 1135 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">49.51 (4.8)</td>
###xml 1135 1147 1135 1147 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">52.19 (13.6)</td>
###xml 1147 1159 1147 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">52.07 (13.3)</td>
###xml 1097 1159 1097 1159 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean age at menopause (SD)*</td><td align="left">49.51 (4.8)</td><td align="left">52.19 (13.6)</td><td align="left">52.07 (13.3)</td></tr>
###xml 1159 1188 1159 1188 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean number of children (SD)*</td>
###xml 1188 1198 1188 1198 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.77 (1.6)</td>
###xml 1198 1208 1198 1208 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.12 (1.7)</td>
###xml 1208 1218 1208 1218 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.10 (1.7)</td>
###xml 1159 1218 1159 1218 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean number of children (SD)*</td><td align="left">1.77 (1.6)</td><td align="left">2.12 (1.7)</td><td align="left">2.10 (1.7)</td></tr>
###xml 1218 1243 1218 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Parity (SD) (&#8805;1 child)*</td>
###xml 1243 1253 1241 1251 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">121 (71.6)</td>
###xml 1253 1264 1251 1262 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2640 (79.4)</td>
###xml 1264 1273 1262 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2761 (79)</td>
###xml 1218 1273 1218 1271 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Parity (SD) (&#8805;1 child)*</td><td align="left">121 (71.6)</td><td align="left">2640 (79.4)</td><td align="left">2761 (79)</td></tr>
###xml 1273 1303 1271 1301 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hormone replacement therapy(%)</td>
###xml 1303 1312 1301 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">27 (21.1)</td>
###xml 1312 1322 1310 1320 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">504 (19.5)</td>
###xml 1322 1332 1320 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">531 (19.6)</td>
###xml 1273 1332 1271 1330 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Hormone replacement therapy(%)</td><td align="left">27 (21.1)</td><td align="left">504 (19.5)</td><td align="left">531 (19.6)</td></tr>
###xml 1332 1345 1330 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean BMI (SD)</td>
###xml 1345 1356 1343 1354 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">27.10 (3.9)</td>
###xml 1356 1367 1354 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26.67 (4.1)</td>
###xml 1367 1378 1365 1376 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26.69 (4.1)</td>
###xml 1332 1378 1330 1376 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean BMI (SD)</td><td align="left">27.10 (3.9)</td><td align="left">26.67 (4.1)</td><td align="left">26.69 (4.1)</td></tr>
###xml 1378 1391 1376 1389 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean WHR (SD)</td>
###xml 1391 1401 1389 1399 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.87 (.09)</td>
###xml 1401 1411 1399 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.87 (.09)</td>
###xml 1411 1421 1409 1419 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.87 (.09)</td>
###xml 1378 1421 1376 1419 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean WHR (SD)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td></tr>
###xml 885 1421 885 1419 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Total studied (%)</td><td align="left">190 (4.7%)</td><td align="left">3513 (95.3)</td><td align="left">3703</td></tr><tr><td align="left">Mean age of entry (SD)*</td><td align="left">67.80 (7.7)</td><td align="left">70.36 (9.6)</td><td align="left">70.24 (9.6)</td></tr><tr><td align="left">Mean age at death (SD)*</td><td align="left">77.30 (8.6)</td><td align="left">84.46 (8.7)</td><td align="left">84.12 (8.8)</td></tr><tr><td align="left">Mean age at menarche (SD)</td><td align="left">13.57 (1.7)</td><td align="left">13.68 (1.8)</td><td align="left">13.67 (1.8)</td></tr><tr><td align="left">Mean age at menopause (SD)*</td><td align="left">49.51 (4.8)</td><td align="left">52.19 (13.6)</td><td align="left">52.07 (13.3)</td></tr><tr><td align="left">Mean number of children (SD)*</td><td align="left">1.77 (1.6)</td><td align="left">2.12 (1.7)</td><td align="left">2.10 (1.7)</td></tr><tr><td align="left">Parity (SD) (&#8805;1 child)*</td><td align="left">121 (71.6)</td><td align="left">2640 (79.4)</td><td align="left">2761 (79)</td></tr><tr><td align="left">Hormone replacement therapy(%)</td><td align="left">27 (21.1)</td><td align="left">504 (19.5)</td><td align="left">531 (19.6)</td></tr><tr><td align="left">Mean BMI (SD)</td><td align="left">27.10 (3.9)</td><td align="left">26.67 (4.1)</td><td align="left">26.69 (4.1)</td></tr><tr><td align="left">Mean WHR (SD)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td></tr></tbody>
###xml 867 1421 867 1419 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Cases</th><th align="left">Controls</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">Total studied (%)</td><td align="left">190 (4.7%)</td><td align="left">3513 (95.3)</td><td align="left">3703</td></tr><tr><td align="left">Mean age of entry (SD)*</td><td align="left">67.80 (7.7)</td><td align="left">70.36 (9.6)</td><td align="left">70.24 (9.6)</td></tr><tr><td align="left">Mean age at death (SD)*</td><td align="left">77.30 (8.6)</td><td align="left">84.46 (8.7)</td><td align="left">84.12 (8.8)</td></tr><tr><td align="left">Mean age at menarche (SD)</td><td align="left">13.57 (1.7)</td><td align="left">13.68 (1.8)</td><td align="left">13.67 (1.8)</td></tr><tr><td align="left">Mean age at menopause (SD)*</td><td align="left">49.51 (4.8)</td><td align="left">52.19 (13.6)</td><td align="left">52.07 (13.3)</td></tr><tr><td align="left">Mean number of children (SD)*</td><td align="left">1.77 (1.6)</td><td align="left">2.12 (1.7)</td><td align="left">2.10 (1.7)</td></tr><tr><td align="left">Parity (SD) (&#8805;1 child)*</td><td align="left">121 (71.6)</td><td align="left">2640 (79.4)</td><td align="left">2761 (79)</td></tr><tr><td align="left">Hormone replacement therapy(%)</td><td align="left">27 (21.1)</td><td align="left">504 (19.5)</td><td align="left">531 (19.6)</td></tr><tr><td align="left">Mean BMI (SD)</td><td align="left">27.10 (3.9)</td><td align="left">26.67 (4.1)</td><td align="left">26.69 (4.1)</td></tr><tr><td align="left">Mean WHR (SD)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td></tr></tbody></table>
###xml 1423 1424 1421 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1421 1437 1419 1435 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">*&#160;<italic>P</italic>-value&#160;&lt;&#160;0.05</p>
###xml 1421 1437 1419 1435 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">*&#160;<italic>P</italic>-value&#160;&lt;&#160;0.05</p></table-wrap-foot>
###xml 813 1437 813 1435 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="25">General characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Cases</th><th align="left">Controls</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">Total studied (%)</td><td align="left">190 (4.7%)</td><td align="left">3513 (95.3)</td><td align="left">3703</td></tr><tr><td align="left">Mean age of entry (SD)*</td><td align="left">67.80 (7.7)</td><td align="left">70.36 (9.6)</td><td align="left">70.24 (9.6)</td></tr><tr><td align="left">Mean age at death (SD)*</td><td align="left">77.30 (8.6)</td><td align="left">84.46 (8.7)</td><td align="left">84.12 (8.8)</td></tr><tr><td align="left">Mean age at menarche (SD)</td><td align="left">13.57 (1.7)</td><td align="left">13.68 (1.8)</td><td align="left">13.67 (1.8)</td></tr><tr><td align="left">Mean age at menopause (SD)*</td><td align="left">49.51 (4.8)</td><td align="left">52.19 (13.6)</td><td align="left">52.07 (13.3)</td></tr><tr><td align="left">Mean number of children (SD)*</td><td align="left">1.77 (1.6)</td><td align="left">2.12 (1.7)</td><td align="left">2.10 (1.7)</td></tr><tr><td align="left">Parity (SD) (&#8805;1 child)*</td><td align="left">121 (71.6)</td><td align="left">2640 (79.4)</td><td align="left">2761 (79)</td></tr><tr><td align="left">Hormone replacement therapy(%)</td><td align="left">27 (21.1)</td><td align="left">504 (19.5)</td><td align="left">531 (19.6)</td></tr><tr><td align="left">Mean BMI (SD)</td><td align="left">27.10 (3.9)</td><td align="left">26.67 (4.1)</td><td align="left">26.69 (4.1)</td></tr><tr><td align="left">Mean WHR (SD)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td></tr></tbody></table><table-wrap-foot><p textid="26">*&#160;<italic>P</italic>-value&#160;&lt;&#160;0.05</p></table-wrap-foot></table-wrap>
###xml 46 58 <span type="species:ncbi:9606">participants</span>
###xml 658 666 <span type="species:ncbi:9606">children</span>
###xml 1174 1182 <span type="species:ncbi:9606">children</span>
###xml 1184 1186 <span type="species:ncbi:9606">SD</span>
###xml 1226 1228 <span type="species:ncbi:9606">SD</span>
###xml 1236 1241 <span type="species:ncbi:9606">child</span>
###xml 1342 1344 <span type="species:ncbi:9606">SD</span>
###xml 1388 1390 <span type="species:ncbi:9606">SD</span>
The total loss of follow-up for the genotyped participants was 8.4% and it was not dependent on ESR1 genotype (P = 0.51). The genotype frequencies of both polymorphisms were in HWE proportions (X2 P = 0.33 for PvuII and X2P = 0.31 for XbaI). In Table 1 we show the baseline characteristics of our study population. We found that all cases (incident and prevalent) were significantly younger at entry than controls (P < 0.001) and also died earlier during follow-up (P < 0.001), when using incident cases only we found the same significant differences (P for age at entry <0.0001, P for age at death <0.0001). We also found that cases had significantly fewer children than controls (P = 0.04). We did not find any significant differences in these baseline characteristics between genotype groups (data not shown). Table 1General characteristics of the study populationCasesControlsTotalTotal studied (%)190 (4.7%)3513 (95.3)3703Mean age of entry (SD)*67.80 (7.7)70.36 (9.6)70.24 (9.6)Mean age at death (SD)*77.30 (8.6)84.46 (8.7)84.12 (8.8)Mean age at menarche (SD)13.57 (1.7)13.68 (1.8)13.67 (1.8)Mean age at menopause (SD)*49.51 (4.8)52.19 (13.6)52.07 (13.3)Mean number of children (SD)*1.77 (1.6)2.12 (1.7)2.10 (1.7)Parity (SD) (>/=1 child)*121 (71.6)2640 (79.4)2761 (79)Hormone replacement therapy(%)27 (21.1)504 (19.5)531 (19.6)Mean BMI (SD)27.10 (3.9)26.67 (4.1)26.69 (4.1)Mean WHR (SD)0.87 (.09)0.87 (.09)0.87 (.09)* P-value < 0.05
###end p 24
###begin p 25
General characteristics of the study population
###end p 25
###begin p 26
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
* P-value < 0.05
###end p 26
###begin p 27
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 14 19 <span type="species:ncbi:9606">women</span>
There were 38 women with previously diagnosed postmenopausal breast cancer who entered the study. During follow-up, 152 were additionally diagnosed. There were no significant differences in the number of cases between the PvuII (P = 0.43 for overall cases) and XbaI genotypes (P = 0.33 for overall cases).
###end p 27
###begin p 28
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 443 448 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 452 456 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 545 550 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 552 553 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 652 659 652 659 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 659 722 659 722 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Odds ratios for breast cancer risk for <italic>PvuII</italic> and <italic>XbaI</italic> genotypes</p>
###xml 659 722 659 722 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Odds ratios for breast cancer risk for <italic>PvuII</italic> and <italic>XbaI</italic> genotypes</p></caption>
###xml 722 722 722 722 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 722 729 722 729 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Overall</th>
###xml 729 737 729 737 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Incident</th>
###xml 737 746 737 746 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prevalent</th>
###xml 722 746 722 746 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Overall</th><th align="left">Incident</th><th align="left">Prevalent</th></tr>
###xml 722 746 722 746 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Overall</th><th align="left">Incident</th><th align="left">Prevalent</th></tr></thead>
###xml 746 751 746 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 746 751 746 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4"><italic>PvuII</italic></td>
###xml 746 751 746 751 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4"><italic>PvuII</italic></td></tr>
###xml 751 753 751 753 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TT</td>
###xml 753 756 753 756 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">Ref</td>
###xml 756 759 756 759 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">Ref</td>
###xml 759 762 759 762 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">Ref</td>
###xml 751 762 751 762 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">TT</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr>
###xml 762 764 762 764 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TC</td>
###xml 764 777 764 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.9 (0.6&#8211;1.4)</td>
###xml 777 790 777 790 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.0 (0.6&#8211;1.6)</td>
###xml 790 803 790 803 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.8 (0.3&#8211;2.1)</td>
###xml 762 803 762 803 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">TC</td><td char="." align="char">0.9 (0.6&#8211;1.4)</td><td char="." align="char">1.0 (0.6&#8211;1.6)</td><td char="." align="char">0.8 (0.3&#8211;2.1)</td></tr>
###xml 803 805 803 805 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CC</td>
###xml 805 818 805 818 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.4 (0.8&#8211;2.2)</td>
###xml 818 831 818 831 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.4 (0.8&#8211;2.5)</td>
###xml 831 844 831 844 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.2 (0.4&#8211;3.3)</td>
###xml 803 844 803 844 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CC</td><td char="." align="char">1.4 (0.8&#8211;2.2)</td><td char="." align="char">1.4 (0.8&#8211;2.5)</td><td char="." align="char">1.2 (0.4&#8211;3.3)</td></tr>
###xml 844 848 844 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 844 848 844 848 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>XbaI</italic></bold>
###xml 844 848 844 848 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4"><bold><italic>XbaI</italic></bold></td>
###xml 844 848 844 848 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4"><bold><italic>XbaI</italic></bold></td></tr>
###xml 848 850 848 850 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 850 853 850 853 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">Ref</td>
###xml 853 856 853 856 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">Ref</td>
###xml 856 859 856 859 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">Ref</td>
###xml 848 859 848 859 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AA</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr>
###xml 859 861 859 861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GA</td>
###xml 861 874 861 874 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.2 (0.8&#8211;1.7)</td>
###xml 874 887 874 887 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.3 (0.8&#8211;2.0)</td>
###xml 887 900 887 900 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.8 (0.4&#8211;1.9)</td>
###xml 859 900 859 900 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GA</td><td char="." align="char">1.2 (0.8&#8211;1.7)</td><td char="." align="char">1.3 (0.8&#8211;2.0)</td><td char="." align="char">0.8 (0.4&#8211;1.9)</td></tr>
###xml 900 902 900 902 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 902 915 902 915 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.3 (0.7&#8211;2.2)</td>
###xml 915 928 915 928 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.5 (0.8&#8211;2.8)</td>
###xml 928 941 928 941 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.5 (0.2&#8211;2.4)</td>
###xml 900 941 900 941 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GG</td><td char="." align="char">1.3 (0.7&#8211;2.2)</td><td char="." align="char">1.5 (0.8&#8211;2.8)</td><td char="." align="char">0.5 (0.2&#8211;2.4)</td></tr>
###xml 746 941 746 941 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="4"><italic>PvuII</italic></td></tr><tr><td align="left">TT</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">TC</td><td char="." align="char">0.9 (0.6&#8211;1.4)</td><td char="." align="char">1.0 (0.6&#8211;1.6)</td><td char="." align="char">0.8 (0.3&#8211;2.1)</td></tr><tr><td align="left">CC</td><td char="." align="char">1.4 (0.8&#8211;2.2)</td><td char="." align="char">1.4 (0.8&#8211;2.5)</td><td char="." align="char">1.2 (0.4&#8211;3.3)</td></tr><tr><td align="left" colspan="4"><bold><italic>XbaI</italic></bold></td></tr><tr><td align="left">AA</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">GA</td><td char="." align="char">1.2 (0.8&#8211;1.7)</td><td char="." align="char">1.3 (0.8&#8211;2.0)</td><td char="." align="char">0.8 (0.4&#8211;1.9)</td></tr><tr><td align="left">GG</td><td char="." align="char">1.3 (0.7&#8211;2.2)</td><td char="." align="char">1.5 (0.8&#8211;2.8)</td><td char="." align="char">0.5 (0.2&#8211;2.4)</td></tr></tbody>
###xml 722 941 722 941 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Overall</th><th align="left">Incident</th><th align="left">Prevalent</th></tr></thead><tbody><tr><td align="left" colspan="4"><italic>PvuII</italic></td></tr><tr><td align="left">TT</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">TC</td><td char="." align="char">0.9 (0.6&#8211;1.4)</td><td char="." align="char">1.0 (0.6&#8211;1.6)</td><td char="." align="char">0.8 (0.3&#8211;2.1)</td></tr><tr><td align="left">CC</td><td char="." align="char">1.4 (0.8&#8211;2.2)</td><td char="." align="char">1.4 (0.8&#8211;2.5)</td><td char="." align="char">1.2 (0.4&#8211;3.3)</td></tr><tr><td align="left" colspan="4"><bold><italic>XbaI</italic></bold></td></tr><tr><td align="left">AA</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">GA</td><td char="." align="char">1.2 (0.8&#8211;1.7)</td><td char="." align="char">1.3 (0.8&#8211;2.0)</td><td char="." align="char">0.8 (0.4&#8211;1.9)</td></tr><tr><td align="left">GG</td><td char="." align="char">1.3 (0.7&#8211;2.2)</td><td char="." align="char">1.5 (0.8&#8211;2.8)</td><td char="." align="char">0.5 (0.2&#8211;2.4)</td></tr></tbody></table>
###xml 652 941 652 941 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="29">Odds ratios for breast cancer risk for <italic>PvuII</italic> and <italic>XbaI</italic> genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Overall</th><th align="left">Incident</th><th align="left">Prevalent</th></tr></thead><tbody><tr><td align="left" colspan="4"><italic>PvuII</italic></td></tr><tr><td align="left">TT</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">TC</td><td char="." align="char">0.9 (0.6&#8211;1.4)</td><td char="." align="char">1.0 (0.6&#8211;1.6)</td><td char="." align="char">0.8 (0.3&#8211;2.1)</td></tr><tr><td align="left">CC</td><td char="." align="char">1.4 (0.8&#8211;2.2)</td><td char="." align="char">1.4 (0.8&#8211;2.5)</td><td char="." align="char">1.2 (0.4&#8211;3.3)</td></tr><tr><td align="left" colspan="4"><bold><italic>XbaI</italic></bold></td></tr><tr><td align="left">AA</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">GA</td><td char="." align="char">1.2 (0.8&#8211;1.7)</td><td char="." align="char">1.3 (0.8&#8211;2.0)</td><td char="." align="char">0.8 (0.4&#8211;1.9)</td></tr><tr><td align="left">GG</td><td char="." align="char">1.3 (0.7&#8211;2.2)</td><td char="." align="char">1.5 (0.8&#8211;2.8)</td><td char="." align="char">0.5 (0.2&#8211;2.4)</td></tr></tbody></table></table-wrap>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
We carried out a logistic regression analysis adjusting for age at entry, age at menopause, BMI, WHR and HRT for both polymorphisms separately (Table 2). Since the T and A alleles of these polymorphisms have been correlated to lower estrogenic effects, we used the TT and AA genotypes as our reference categories in the analyses. There were no significant differences in risk for breast cancer among carriers of the different genotypes of the PvuII or XbaI polymorphisms in the ESR1 gene. There was a non-significant tendency of the C allele of PvuII (P-for trend = 0.22) and G allele of the XbaI (P-for trend 0.26) to be over represented in patients. Table 2Odds ratios for breast cancer risk for PvuII and XbaI genotypesOverallIncidentPrevalentPvuIITTRefRefRefTC0.9 (0.6-1.4)1.0 (0.6-1.6)0.8 (0.3-2.1)CC1.4 (0.8-2.2)1.4 (0.8-2.5)1.2 (0.4-3.3)XbaIAARefRefRefGA1.2 (0.8-1.7)1.3 (0.8-2.0)0.8 (0.4-1.9)GG1.3 (0.7-2.2)1.5 (0.8-2.8)0.5 (0.2-2.4)
###end p 28
###begin p 29
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
Odds ratios for breast cancer risk for PvuII and XbaI genotypes
###end p 29
###begin p 30
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 514 519 514 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 892 898 892 898 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 917 921 917 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 898 957 898 957 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Meta-Analyses ESR1 <italic>XbaI</italic> polymorphism and breast cancer risk</p>
###xml 898 957 898 957 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Meta-Analyses ESR1 <italic>XbaI</italic> polymorphism and breast cancer risk</p></caption>
###xml 957 957 957 957 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2007_9562_Fig1_HTML" id="MO1"/>
###xml 892 957 892 957 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="31">Meta-Analyses ESR1 <italic>XbaI</italic> polymorphism and breast cancer risk</p></caption><graphic position="anchor" xlink:href="10549_2007_9562_Fig1_HTML" id="MO1"/></fig>
###xml 957 963 957 963 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 982 987 982 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 963 1023 963 1023 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Meta Analysis ESR1 <italic>PvuII</italic> polymorphism and breast cancer risk</p>
###xml 963 1023 963 1023 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Meta Analysis ESR1 <italic>PvuII</italic> polymorphism and breast cancer risk</p></caption>
###xml 1023 1023 1023 1023 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2007_9562_Fig2_HTML" id="MO2"/>
###xml 957 1023 957 1023 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="32">Meta Analysis ESR1 <italic>PvuII</italic> polymorphism and breast cancer risk</p></caption><graphic position="anchor" xlink:href="10549_2007_9562_Fig2_HTML" id="MO2"/></fig>
To evaluate our data together with those in the literature we performed meta-analyses. We identified nine articles studying the relation between XbaI and PvuII polymorphisms and the risk of breast cancer [4, 9-12, 21-24]. We excluded from our analyses one study [11], since the data was used in another study [4]. Furthermore, two studies were excluded since genotype frequencies of controls were out of HWE proportions [9, 10]. Using the random effects model we did not find any difference in risk among XbaI and PvuII genotypes (Figs. 1 and 2). High inter-study heterogeneity can render the interpretation of the results of a meta-analysis difficult and although we found high heterogeneity in the G/A versus GG comparison there was no significant heterogeneity in the other three comparisons. Additionally, the evaluation of the funnel plots did not suggest evidence for publication bias. Fig. 1Meta-Analyses ESR1 XbaI polymorphism and breast cancer riskFig. 2Meta Analysis ESR1 PvuII polymorphism and breast cancer risk
###end p 30
###begin p 31
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
Meta-Analyses ESR1 XbaI polymorphism and breast cancer risk
###end p 31
###begin p 32
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
Meta Analysis ESR1 PvuII polymorphism and breast cancer risk
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 172 177 <span type="species:ncbi:9606">women</span>
We performed an association study to evaluate the relationship of two well-studied polymorphisms in the ESR1 gene and the risk of breast cancer in Caucasian postmenopausal women from the Rotterdam Study. Using logistic regression analysis, we found no evidence of effect, with only a non-significant increase in breast cancer risk for AA carriers of the XbaI polymorphism (overall OR = 1.3, 95% CI = 0.7-2.2) and for TT carriers of the PvuII variant (overall OR = 1.4, 95% CI = 0.8-2.2). Additionally we performed meta-analyses of published data to examine the effect of both polymorphisms. These meta-analyses also suggest there are no differences in risk among genotype groups of these two ESR1 variants.
###end p 34
###begin p 35
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI</italic>
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
The XbaI and PvuII polymorphisms are situated in intron 1 and their functionality has not yet been demonstrated. Moreover, it has been suggested their effects could be the result of high linkage disequilibrium with functional variants that affect sensitivity to estrogen [13].
###end p 35
###begin p 36
###xml 392 397 <span type="species:ncbi:9606">women</span>
One of the limitations of our study is the limited number of breast cancer cases present in our population. Nevertheless, we have sufficient power (beta = 0.8) to detect effects of 1.6 or higher. We further conducted meta-analyses off all studies conducted to date. Our data suggests that these two polymorphisms do not play a role in the susceptibility of breast cancer in elderly Caucasian women.
###end p 36
###begin title 37
Acknowledgements
###end title 37
###begin p 38
A Arias Vasquez is supported by a grant from the Center of Medical Systems Biology, grant # 297-2003. The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam.
###end p 38
###begin p 39
These sponsors had no role in study design, data collection, data interpretation, or the writing of this report. A Arias Vasquez contributed with the design of the study and also participated in the data analyses. CM van Duijn participated in the design and writing of the manuscript. F Rivadeneira, J Witteman, HAP Pols, BHCh Stricker, AG Uitterlinden and A Hofman aided in the data collection and the writing of this manuscript as well.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
###end article-title 41
###begin article-title 42
Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention
###end article-title 42
###begin article-title 43
Estrogen receptor alpha gene polymorphisms and breast cancer risk
###end article-title 43
###begin article-title 44
Full sequencing analysis of estrogen receptor-alpha gene polymorphism and its association with breast cancer risk
###end article-title 44
###begin article-title 45
###xml 20 25 <span type="species:ncbi:9606">human</span>
Localization of the human oestrogen receptor gene to chromosome 6q24-q27 by in situ hybridization
###end article-title 45
###begin article-title 46
###xml 28 33 <span type="species:ncbi:9606">human</span>
Genomic organization of the human oestrogen receptor gene
###end article-title 46
###begin article-title 47
###xml 22 27 <span type="species:ncbi:9606">human</span>
PvuII RFLP inside the human estrogen receptor gene
###end article-title 47
###begin article-title 48
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
###end article-title 48
###begin article-title 49
Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai breast cancer study
###end article-title 49
###begin article-title 50
Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk
###end article-title 50
###begin article-title 51
###xml 96 101 <span type="species:ncbi:9606">women</span>
Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women
###end article-title 51
###begin article-title 52
Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood
###end article-title 52
###begin article-title 53
Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk
###end article-title 53
###begin article-title 54
###xml 34 39 <span type="species:ncbi:9606">women</span>
Height in pre- and postmenopausal women is influenced by estrogen receptor alpha gene polymorphisms
###end article-title 54
###begin article-title 55
Determinants of disease and disability in the elderly: the Rotterdam Elderly Study
###end article-title 55
###begin article-title 56
Quetelet index as indicator of obesity
###end article-title 56
###begin article-title 57
Genepop (version 1.2): population genetics software for exact tests and ecumenism
###end article-title 57
###begin article-title 58
Meta-analysis in clinical trials
###end article-title 58
###begin article-title 59
A comparison of methods to detect publication bias in meta-analysis
###end article-title 59
###begin article-title 60
Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China
###end article-title 60
###begin article-title 61
Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study
###end article-title 61
###begin article-title 62
A multigene test for the risk of sporadic breast carcinoma
###end article-title 62
###begin article-title 63
The estrogen receptor alpha gene and breast cancer risk (The Netherlands)
###end article-title 63

